These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 14069010)

  • 1. STUDIES IN THALASSAEMIA MAJOR.
    ROBERTSON EF; MAXWELL GM; ELLIOTT RB
    Med J Aust; 1963 Oct; 2():705-7. PubMed ID: 14069010
    [No Abstract]   [Full Text] [Related]  

  • 2. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Beta-thalassemia major in children and adolescents in Denmark].
    Jung A; Main KM; Scheibel E; Peitersen B; Clausen N; Erichsen G; Schmiegelow K; Illum N
    Ugeskr Laeger; 2002 Dec; 164(49):5803-6. PubMed ID: 12523224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
    Taher A; Hershko C; Cappellini MD
    Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Patient compliance in iron-chelating therapy of beta-thalassemia major].
    Di Gregorio F; Romeo MA; Tasca R; Passaniti G
    Minerva Pediatr; 1983 May; 35(10):489-93. PubMed ID: 6877194
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 7. Liver iron stores before and after bone marrow transplantation for thalassemia.
    Politi P; Lucarelli G; Capriotti L; Salvadori P; Dardanelli C; Barbanti I
    Prog Clin Biol Res; 1989; 309():281-9. PubMed ID: 2675096
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival in thalassemia with conventional treatment.
    Borgna-Pignatti C; Zurlo MG; DeStefano P; DiGregorio F; Di Palma A; Piga A; Melevendi C; Burattini MG; Terzoli S; Masera G
    Prog Clin Biol Res; 1989; 309():27-33. PubMed ID: 2675094
    [No Abstract]   [Full Text] [Related]  

  • 9. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 10. Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major.
    Noetzli LJ; Coates TD; Wood JC
    Br J Haematol; 2011 Jan; 152(2):229-33. PubMed ID: 21118197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of treatment with long-term chelating agents on iron overload in thalassaemia.
    Letsky EA; Flynn DM; Barry M
    Br J Haematol; 1973 Aug; 25(2):285. PubMed ID: 4726921
    [No Abstract]   [Full Text] [Related]  

  • 12. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 13. [The endocrine complications in thalassemia major].
    Anastasi S; Caruso V; Magnano C; Leocata A
    Pediatr Med Chir; 1991; 13(1):63-5. PubMed ID: 2052458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ; Spyrou A; Kolnagou A
    Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IRON ABSORPTION IN THALASSAEMIA.
    BANNERMAN RM; CALLENDER ST; HARDISTY RM; SMITH RS
    Br J Haematol; 1964 Oct; 10():490-5. PubMed ID: 14218451
    [No Abstract]   [Full Text] [Related]  

  • 16. [Status of iron metabolism and erythropoietic proliferation in children with various genotypes of thalassemia].
    Mai HR; Li CG; Wang Y; Shi HS; Zhao WL; Chen YS; Chen XW
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Aug; 12(8):602-4. PubMed ID: 20704788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical management of beta-thalassemia.
    Lerner N
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.